Safety and Efficacy of Secukinumab in Mild Psoriasis

Exclusion Criteria

• •1. Has a nonplaque form of psoriasis (eg, erythrodermic, guttate, or pustular)
• •2. Has previously received Secukinumab or other biologics
• •3. History of Inflammatory Bowel Disease (IBD)
• •4. History of Rheumatoid Arthritis
• •5. Use of topical treatments for psoriasis, including steroids, vitamin D derivatives, vitamin A derivatives, salicylic acid, tar (except moisturizers) and/or ultraviolet A light (UVA)/UVB phototherapy within the last 2 weeks (if these have used them, the participant needs to wash off of them for at least 2 weeks after signing consent prior to baseline)
• •6. Is pregnant, nursing, or planning a pregnancy (both men and women) within 5 months following the last administration of study drug
• •7. Has recently received or is planning to receive a vaccination while on the study
• •8. HIV positive
• •9. Chronic untreated hepatitis C, positive hepatitis B surface antigen and acute hepatitis A infection
• •10. Known tuberculosis (TB) or evidence of TB infection. Subjects with a positive QuantiFERON; TB test or a positive purified protein derivate (PPD) skin test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active TB.
• •11. Any severe, progressive or uncontrolled medical condition at screening that in the judgment of the investigator prevents the subject from participating in the study.